Compare iShares MSCI Australia ETF (EWA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Australia ETF trades at $28.59 (market cap $1.17B), while Merck & Co., Inc. trades at $146.31 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 300.2× iShares MSCI Australia ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Merck & Co., Inc. for 98 Days on average.
| EWA | MRK | |
|---|---|---|
Market Cap | $1.17B | $351.28B |
Volume | 2,121,231 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $156.43 |
52-Week Low | $24.95 | $82.49 |
Typical Hold Time | 61 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.56, up 1.17% today, but technical indicators are bearish with all moving averages signaling sell. The ETF provides exposure to Australian equities, heavily weighted toward commodities and financials. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns due to rising oil prices.
The outlook remains cautious amid bearish technicals and macroeconomic headwinds, though some analysts see upside potential from commodity strength. Risks include persistent inflation, tight monetary policy, and reliance on raw material exports. Investors should weigh technical weakness against long-term commodity-driven growth prospects.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
